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ABSTRACT 
Children with the clinical features of Chronic Tonsillitis coming under the age group 3-12 years were 
included in the study. The patients were randomly allocated in to the study group and control group 
using simple random sampling technique. In the study group the dose of Varabrihatyadi Kashaya was 
fixed as follows, in the age group 3-6 years: 10ml bd before food, in the age group 6-9 years: 20ml bd 
before food, in the age group 9-12 years: 30ml bd before food. Sarapunkha lepa was applied around 
the neck where enlarged lymph nodes were found. Frequency of paste was fixed as two times daily 
and at each time, it is kept until it becomes dry. At the same time those in the control group were 
subjected to external application of Sarapunkha lepa only. Both the groups were followed for a period 
of 1 month after the scheduled course of intervention. Routine blood investigations were also carried 
out before and after the study. The data were analyzed using the most appropriate statistical tests. 
Significant changes were obtained in the clinical parameters in the study group used for assessment 
such as recurrent attacks of sore throat, pain in the throat, pain on swallowing, difficulty in 
swallowing, halitosis, mouth breathing, hoarseness of voice, chocking spells at night, size of the tonsil, 
congestion of pillars, oedema of the uvula, deviation of the uvula and lymph node enlargement. There 
was a significant change in the routine blood investigations also. Moreover the trial drug sustained its 
potential action even during the follow up period. The effect of control drug was insignificant. The 
final evaluation proved that combination of Varabhrihathyadi Kashaya and Sarapunkha lepa was 
effective in reducing the signs and symptoms of Chronic Tonsillitis in children of 3-12 yrs age group. 
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INTRODUCTION 
Ayurveda an ancient traditional system of 
medicine is considered the oldest system of health 
care, with literature going back 5000 years and an 
oral tradition that is much older. Ayurveda helps the 
healthy person to maintain health and the diseased 
person to regain health. Kaumarabhrithya is one 
among the most important branches of Ayurveda 
dealing with child care. The knowledge attitude and 
practice of this childcare system have to be uplifted 
for the welfare of entire child population. The 
researchers are to be done in this field to ensure the 
development of Ayurvedic Paediatric Department.  
Sore throat is a common condition in primary 
care. As many as 1 in 10 people suffer recurrent 
episodes of tonsillitis. The cost per year to the NHS 
for primary care consultations, before investigation 
and treatment, for sore throats is estimated at 60 
million pounds. It is also estimated that 35 million 
work and school days are lost per year because of 
sore throats. Tonsillitis most often occurs in children; 
however, the condition rarely occurs in children 
younger than 2 years. Acute tonsillitis is a common 
condition often seen in children aged 5–10 and young 
adults aged 15–25. Chronic Tonsillitis is usually due 
to the complication of improperly managed tonsillitis 
that affects child’s day-to-day performances. If not 
managed properly it may lead to systemic disorders 
namely rheumatic fever, acute glomerulo-nephritis 
and even interferes with normal growth and 
development of child. 
  Chronic tonsillitis can be simulated with 
different diseases mentioned in Ayurvedic classics. It 
can be compared with different diseases like Apachi, 
Kanda Salookam, Kapha Pitta Sopham, Galavidradi, 
Tundikerika, etc. Precise comparison cannot be 
possible in any of these disorders. It also gives an 
inference that in that ancient era tonsillitis was not as 
prevalent and serious problem as it is now. 
 Apachi is described as generalized chronic 
lymphadenitis due to various etiologies. Specific sites 
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of Apachi include Kaksha (axilla) and Vamkshana 
(groin) that gives an inference that it is not a simple 
oral disease. Other clinical features like suppuration, 
oozing and synonym like Gandamala (cervical 
lymphadenitis) of Apachi points out it into a clinical 
condition similar to Scrofuloderma found with 
tuberculosis.[1] The Kanda Salukam, an oral disease 
mentioned in Astanga Hridaya and Susrutha 
Samhitha, cannot be compared with chronic 
tonsillitis, because size and shape of Salukam which 
is explained as Kolaphala is not matching with size 
and shape of tonsils and Saluka’s specific site other 
than throat is not mentioned.[2]  
Kapha Raktha Sopha, Kapha Pitta Sopha, Gala 
Vidradi are all umbrella terms which do not have any 
specificity and is applicable to diseases manifesting in 
any part of the body. 
Even though exact correlation is not possible, 
chronic tonsillitis can be simulated with Tundikerika, 
a Mukha roga (oral disease) explained in various 
classics. Susrutha considered Tundikerika under 
Talugata roga[3] (according to Susrutha, Talu is one 
among seven basic units of oral cavity) while 
Vagbhata described it under Kantagata roga 
(according to Vagbhata Kanta is one among eight 
basic units of oral cavity).[4] 
Lot of Ayurvedic formulations are widely 
used in Kerala in the management of Chronic 
Tonsillitis; most of them are herbal in origin. 
However many of them are yet be clinically proved 
and analysed statistically which is a part of present 
research methodology.  
In the present study it was planned to 
evaluate the combined effect of Varabhrihathyadi 
Kashaya and Sarapunkha Lepa in chronic tonsillitis. 
The reference of above mentioned formulations are 
given in Arogyakalpadrumam[5], a traditional 
Ayurvedic paediatric textbook. The combination of 
decoction and paste is mentioned in the treatment of 
Apachi[6] (a clinical condition similar to chronic 
lymphadenitis). Since tonsil is a lymphoid tissue, the 
above combination is taken in this clinical trial to 
assess its efficacy in chronic tonsillitis. 
  In the present scenario, well-established 
clinical trials like Randomized Controlled Trial have 
highest level of significance to prove the efficacy. 
Therefore, a therapeutic single blinded, randomized 
controlled trial was designed to prove the combined 
effect of Varabhrihathyadi Kashayam and Sarapunkha 
Lepam in chronic tonsillitis. 
MATERIALS AND METHODS 
Aims and objectives 
The aim of the study was to evaluate the 
combined effect of Varabhrihatyadi kashayam 
(decoction) and Sarapunkha lepam (paste) in Chronic 
Tonsillitis in children of age group 3 - 12 years and to 
evaluate its sustained effect for a period of one 
month. 
Ethical considerations 
Ethics are principles of right conduct. Ethical 
principles always represent basic human values. 
Efforts were made to maximize the benefits to the 
subjects (beneficence) and subject should suffer no 
harm (non-malfeasance) in the present study. 
Hypothesis 
 The research hypothesis is a tentative 
statement that can be tested by a scientific research 
design. Since this clinical research is concerned with 
relationships between observations or variables, a 
research hypothesis was developed. 
Null hypothesis 
Combination of Varabhrihatyadi kashayam 
and Sarapunkha lepam is not effective in chronic 
tonsillitis in children in the age group between 3 
years and 12 years. 
Alternate Hypothesis 
Combination of Varabhrihatyadi kashayam 
and Sarapunkha lepam is very effective in chronic 
tonsillitis in children in the age group between 3 
years and 12 years. 
Variables 
The experimental variable was the 
combination of Varabhrihatyadi decoction and 
Sarapunkha paste. Change noted in the condition of 
Chronic Tonsillitis in children was the dependent 
variable. A number of intervening variables such as 
diet, age, sex, seasonal change, constitution etc. kept 
constant by keeping a control. 
Drug selection  
The combination of Varabhrihatyadi 
kashayam and Sarapunkha paste is explained in the 
context of Treatment of Apachi (a clinical condition 
similar to chronic lymphadenitis). Even though the 
combination is not directly mentioned for chronic 
tonsillitis, the drugs in the decoction possess anti 
inflammatory, antibacterial, antipyretic, diuretic, 
analgesic and immunomodulatory properties. The 
paste of Sarapunkha, which is processed in Thriphala 
decoction, supposed to possess anti-inflammatory 
properties. Thus, the combination becomes an ideal 
drug for chronic tonsillitis. 
Raw materials for the preparation of the trial 
drugs were procured from a reputed raw drug shop, 
at Thiruvananthapuram. The drugs were powdered 
in a micro pulverizer by maintaining the standards 
for an infusion. The care takers of patients were 
requested to prepare the infusion with prescribed 
quantities of powder. The root of Sarapunkha was 
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powdered and provided to care takers to prepare the 
paste in Thriphala infusion.  
Control drug 
External application of Sarapunkha paste 
over the neck (where enlarged tonsils can be 
palpated) was taken as the intervention in the 
Control Group. Thriphala decoction was the liquid 
base for preparing the paste. Care takers of patients 
were requested to prepare Thriphala infusion with 
powdered Thriphala. They were requested to soak 
Sarapunkha powder in Thriphala decoction overnight 
and grind well to prepare a paste. They were asked to 
apply the paste over the neck (where enlarged tonsil 
can be palpated) of the patients. 
Research Population 
The children affected with Tundikerika 
(Chronic tonsillitis) with age limit of 3 to 12 years 
attending the outpatient unit of department of 
Kaumarabhrithya, Govt. Ayurveda College Hospital 
for Women and Children Poojappura, 
Thiruvananthapuram was the research population of 
the study. Patients from throughout Trivandrum 
district are attending the OPD section of department 
of Kaumarabhrithya.  
Inclusion Criteria 
Children of 3 to 12 years presenting with 
clinical manifestations of chronic tonsillitis were 
included in the study. As tonsillitis is infrequently 
occurs in children younger than 2 years children 
from 3 years were included in the study. Since the 
children only up to 12 years attend the OPD unit, the 
maximum age limit kept was twelve years. 
Exclusion Criteria 
Children suffering from acute tonsillitis, 
complications like peritonsillar abscess and other 
systemic illness were excluded from the study.  
Time and Duration of the Study 
Study was started on October 2011 and 
completed by March 2013 with the duration of 18 
months. 
Technique of Data Collection 
As per the inclusion criteria, the children 
suffering from chronic tonsillitis (Tundikerika) were 
thoroughly interrogated; history and facts were 
noted in a specially designed clinical proforma. It 
included past illness, physical findings, clinical 
manifestations, and treatment history.  
To ensure sufficient accuracy relevant data 
were collected by personal observation of salient 
features and relevant history that included 
environmental conditions of individuals, their 
characteristics such as age, sex, dietary habits, 
treatment or therapeutic procedures and responses 
of these individuals. The clinical qualitative 
parameters were graded and their variations were 
recorded by researcher itself. Quantitative data 
relating to the routine haematological study were 
collected from the Laboratory of Govt. Ayurveda 
College Hospital for women and children Poojappura. 
Periodical assessment was done at an interval of 10 
days.  
Treatment Schedule 
Children of age group of 3 - 12yrs attending 
the outpatient unit of Kaumara-bhritya department 
were screened for Chronic Tonsillitis using clinical 
and laboratory parameters. 
An informed consent of parents was obtained 
before recruiting child into the trial. The subjects 
were recruited randomly in to two groups for the 
trial, the Study Group and Control Group; were made 
identical in all aspects except for the intervention. 
Both the groups were followed for a period of 1 
month after the scheduled course of intervention. 
Duration of the treatment was 60 days. In the study 
group as per the recommendations of Acharya 
Sargadhara the dose of Varabrihatyadi decoction was 
fixed as follows, in the age group 3-6 years: 10ml bd 
before food, in the age group 6-9 years: 20ml bd 
before food, in the age group 9-12 years: 30ml bd 
before food. Sarapunkha Churna was made into paste 
by adding Thriphala decoction and applied around 
the neck where enlarged lymph nodes can be 
palpated. Duration of paste was fixed as two times 
daily and at each time, it is kept until it becomes dry. 
At the same time, those in the control group were 
subjected to external application of Sarapunkha paste 
only. Both the groups were followed for a period of 1 
month after the scheduled course of intervention. 
Assessment Criteria 
Both the groups were assessed before and after the 
study by observing 
1. Graded clinical signs and symptoms  
2. Routine blood investigations Hb, T.C, D.C and 
E.S.R. 
Data Analysis 
Data were consolidated by using statistical 
methods. The efficacy of the intervention was 
evaluated and conclusions were drawn by using 
statistical tests such as Wilcoxon Signed Ranks Test 
and Mann Whitney Rank Sum Test. 
Trial drug 
The combination of Varabhrihatyadi 
kashayam (decoction) for internal use and 
Sarapunkha lepam (paste) was administered in the 
Study Group. The reference of above mentioned 
formulations from Arogyakalpadrumam, a traditional 
Ayurvedic Paediatric Textbook. The combination of 
decoction and paste is mentioned in the treatment of 
Apachi. (a clinical condition similar to chronic 
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lymphadenitis). Since tonsil is a lymphoid tissue, the 
above combination is taken in this clinical trial to 
assess its efficacy in chronic tonsillitis 
Collection of Raw Materials 
The ingredients of Varabhrihatyadi decoction include 
following drugs.  
Amalaki (Emblica officinale), Hareethaki 
(Terminalia chebula), Vibeethaki (Terminalia 
bellerica), Bhrihati (Solanum indicum), Nimba 
(Azadirachta indica), Rajani (Curcuma longa), Vrisha 
(Adathoda vasica), Daru (Cedrus deodar), Patola 
(Trichosanthes dioica) and Sarapunkha (Tephrosa 
purpurea). 
The root of Sarapunkha (Tephrosia purpurea) 
is used for the preparation of paste for the topical 
application. For making Sarapunkha (Tephrosia 
purpurea) paste, the decoction of Thriphala is used as 
the liquid base for soaking and grinding Sarapunkha 
(Tephrosia purpurea) powder. Thriphala decoction is 
made by using powder of Emblica officinale, 
Terminalia chebula and Terminalia bellerica in equal 
quantity. 
The required amount of raw drug is collected 
from a reputed Ayurvedic raw drug shop at 
Thiruvananthapuram. The authenticity of these drugs 
is then approved by the Department of Dravyaguna at 
Govt. Ayurveda College, Thiruvananthapuram.  
Quantity of drugs in Study Group 
The below mentioned amount of drugs were 
used for preparing the medicines in the study group. 
Table 1: Drugs for Varabhrihatyadi decoction 
Sl.No Drug Parts used Quantity 
1 Amalaki (Emblica officinale) Fruit 2 kg 
2 Hareethaki (Terminalia chebula) Fruit 2 kg 
3 Vibeethaki (Terminalia bellerica)  Fruit 2 kg 
4 Bhrihati (Solanum indicum) Root 2 kg 
5 Nimba (Azadirachta indica)  Bark 2 kg 
6 Rajani (Curcuma longa)  Stem 2 kg 
7 Vrisha (Adathoda vasica)  Root 2 kg 
8 Devadaru (Cedrus deodar) Heart wood 2 kg 
9 Patola (Trichosanthes dioica) Root 2 kg 
10 Sarapunkha (Tephrosa purpurea)  Root 2 kg 
Table 2: Drugs for Sarapunkha (Tephrosia purpurea) paste 
SL No Drug Part used Quantity 
1 Sarapunkha Root 3 kg 
Table 3: Preparing Thriphala decoction (liquid base) for soaking and grinding of Sarapunkha 
Sl.No Drug Part used Quantity 
1. Amalaki (Emblica officinale)  Fruit 1 kg 
2. Hareethaki (Terminalia chebula)  Fruit 1 kg 
3. Vibeethaki (Terminalia bellerica)  Fruit 1 kg 
Method of Preparation of Drugs in Study Group 
Preparation of Varabhrihatyadi Decoction 
The Varabhrihatyadi decoction was 
administered in the form of infusion (Phanta 
kashayam). In order to prepare an infusion, coarse 
powder of ingredients is required. So all drugs were 
washed, cleaned and dried in sunlight and then 
powdered well in a micro pulverizer. Powder was 
packed in airtight containers. Care takers of patients 
were requested to prepare an infusion with 
prescribed quantity of powder and advised to take 
twice daily before food. 
Preparation of Sarapunkha Paste 
Thriphala decoction was the liquid base for 
preparing the paste. Care takers of patients were 
requested to prepare Thriphala infusion with 
powdered Thriphala. They were requested to soak 
Sarapunkha powder in Thriphala decoction overnight 
and grind well to prepare a paste. They were asked to 
apply the paste over the neck (where enlarged tonsil 
can be palpated) of the patients. 
The Control Group 
The use of placebo may not be always 
possible due to ethical consideration, so external 
application of Sarapunkha paste over the neck 
(where enlarged tonsils can be palpated) was taken 
as the intervention in the control group. The paste is 
supposed to possess anti-inflammatory property. The 
paste is mentioned in Arogyakalpadrumam in the 
context of the treatment of Apachi for the reduction 
of enlarged lymph glands. 
Method of preparation of drug in Control Group 
Care takers of patients were requested to 
prepare Thriphala infusion with powdered Thriphala. 
They were requested to soak Sarapunkha powder in 
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Thriphala decoction overnight and grind well to 
prepare a paste. They were asked to apply the paste 
over the neck (where enlarged tonsil can be 
palpated) of the patients. 
Research design 
Therapeutic, single blinded, Randomized Controlled 
Trial. 
Sampling 
Simple Random sampling was followed in the 
study. Selected subjects were randomly divided into 
two groups, Study Group and Control Group by using 
Table of Random Number. 
Sampling Element 
Sampling element was children of 3 to 12 years 
affected with Chronic Tonsillitis. 
Sampling Fraction 
Children in the age groups 3 to 6 years, 6 to 9 
years and 7 to 12 years with clinical features of 
Chronic Tonsillitis attending the outpatient section of 
Department of Kaumarabhritya, Govt. Ayurveda 
College, Thiruvananthapuram were the sampling 
fraction. 
Observation Interpretation and Analysis 
Demographic data 
1. From the above table it is evident that 60% of the 
subjects were from the age group 7-12 years and 
40% were in the age group 3-6 years. 
2. Sex wise Distributions showed that among the 
subjects, 58% were males and 42% were females. 
3. The distribution of the subject’s religious status 
was shown in the above table. 80% of the subjects 
were from Hindu community and the remaining 
17% from other two communities 
4. The socio economic status of the subjects was 
shown in the above table. From the above table it 
is clear that 78% of the subjects were from the 
middle socio economic status group and 12% from 
poor socio economics status and 10% from the 
upper socio economic status. 
5. The domicile status of the study revealed that 58% 
of the subjects were from the urban area and 42% 
of the subjects were from the rural area. The 
status of the food consumption is concerned; all 
subjects were consuming mixed diet. 
6. According to the educational status 73% of the 
subjects were attending above the primary school 
level and 27% were below primary school level 
Clinical picture 
1. Over all 65% of the subjects were more than or 
equal to 3 years duration of the onset of disease, 
28% were more than or equal to 2 years of onset 
of disease and rest of them were having an onset 
of 1 year or less. 
2. Maximum children (48%) were of Vata kapha 
prakrithi, followed by Pitha kapha prakrithi (42%) 
and Vata pitha prakrithi (10%). 
3. Majority of subjects (48%) had Mandangi (poor 
digestive capacity) rest 37% had Vishamagni 
(inconsistent digestive capacity), 10% had 
Teekshana agni and 5% had Sama agni. 
4. Distribution according to nutritional status 
showed that 32% had poor nutritional status, 25% 
had moderate nutritional status, 43% had 
adequate nutrition. 
5. Distribution according to the type of Chronic 
Tonsillitis showed that 10% had chronic follicular 
tonsillitis, 38% had chronic parenchymatous 
tonsillitis and 52% had chronic fibroid tonsillitis. 
Data related to response to treatment 
Table 4: Comparison of change in frequency of recurrent attacks of sore throat in subsequent follow-up 
within the group 
Recurring attacks of sore throat Group No. of patients Wilcoxon W value P value 
BT - AT 
Study 20 - 124 0.001 
Control 20 -12 0.135 
AT - AFU 
Study 20 -140 0.001 
Control 20 -12 0.125 
The remarkable improvement is statistically significant (p=0.001). However, in the control group there 
was no significant improvement. From this data, it is clear that the drug was effective in reducing the recurring 
attack of sore throat and there was sustained action even during follow up. 
Table 5: Comparison of change in the frequency of recurrent attacks of sore throat between study and 
control group 
Recurring attacks of sore 
throat 





Study 20 1 
440 0.001 
Control 20 2 
AFU 
Study 20 1 
470 0.001 
Control 20 3 
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In the study group the recurrent attack of the sore throat is showing statistically significant difference 
(p=0.001) after treatment as well as follow-up period. This implies that the trial drug was very effective in 
reducing the recurring attack of sore throat than that of the control group and further retained the effect during 
the follow-up period.  
Table 6: Comparison of change in irritation in the throat within the group and subsequent follow-up 
period 
Irritation in the throat Group No. of patients Wilcoxon W value P value 
BT – AT 
Study 20 110 0.001 
Control 20 130 0.001 
AT – AFU 
Study 20 110 0.001 
Control 20 130 0.001 
The comparison of the irritation in the throat within the study and control group of patients revealed high 
significant improvement (p=0.001) after treatment and subsequent follow-up. This indicates that both trial 
drug and control drug were equally effective in reducing the irritation of throat. 
Table 7: Comparison of change in irritation in the throat between study and control groups 





Median Mann Whitney U test P value 
AT 
Study 20 1 
360 0.569 
Control 20 2 
AFU 
Study 20 1 
365 0.557 
Control 20 2 
The difference in the median value between the two groups is not great enough to exclude the possibility that 
the difference is due to random sampling variability. There is no statistical significant difference after treatment 
as well as after follow-up. This shows that both the treatments were equally effective in reducing irritation of 
throat. 
Table 8: Comparison of change in pain in the throat in subsequent follow-up within the group 
Pain in the throat Group No. of patients Wilcoxon W value P value 
BT-AT 
Study 20 - 184 0.001 
Control 20 -25 0.115 
AT-AFU 
Study 20 -184 0.001 
Control 20 -29 0.089 
The comparison of the pain in throat in the study group showed that there was significant effect (p=0.001) after 
the treatment as well as after follow-up. In the control group, this effect was not statistically significant. Thus, it 
showed that trial drug was very effective in reducing pain 
Table 9: Comparison of change in the pain in throat between study and control group 
Pain in the throat Group No. of patients Median Mann Whitney U test P value 
AT 
Study 20 0 
480 0.001 
Control 20 2 
AFU 
Study 20 0 
483 0.001 
Control 20 3 
The symptom, pain in the throat is significantly (p=0.001) reducing after treatment as well as follow-up period. 
This implies that the trial drug was very effective in reducing the pain in the throat than that of the control 
group and further retained the effect during the follow-up period.  
Table 10: Comparison of change in the pain on swallowing in subsequent follow-up within the group 
Pain on swallowing Group No. of patients Wilcoxon W value P value 
BT-AT 
Study 20 - 110 0.001 
Control 20 -20 0.075 
AT-AFU 
Study 20 -110 0.001 
Control 20 -20 0.075 
Wilcoxon Signed Rank test showed that there is highly significant change in the pain on swallowing in the study 
group (p<0.001) whereas in the control group change is not significant. This proved that the efficacy of the trial 
drug given to the study group is reducing the symptom. This effect was sustained during the follow up period. 
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Table 11: Comparison of change in the pain on swallowing between study and control group 
Pain on 
swallowing 
Group No. of 
patients 
Median Mann Whitney U test P value 
AT 
Study 20 0 
420 0.005 
Control 20 2 
AFU 
Study 20 0 
431 0.003 
Control 20 1 
The pain on swallowing is significantly reduced (p=0.005) after treatment. In the follow up period this effect 
was sustained (p=0.003). This implies that the trial drug was very effective in reducing the pain on swallowing 
than that of the control drug and further the effect was prolonged in the follow-up period. 
Table 12: Comparison of change in the difficulty in swallowing on subsequent follow-up within the 
group 
Difficulty in swallowing Group No. of patients Wilcoxon W value P value 
BT-AT 
Study 20 - 126 0.001 
Control 20 -15 0.093 
AT-AFU 
Study 20 -126 0.001 
Control 20 -15 0.076 
The comparison of the difficulty in swallowing showed that there was remarkably reducing the difficulty in 
swallowing in the study group after the treatment as well as after the follow-up. This remarkable improvement 
is statistically significant (p=0.001). However, in the control group there was no significant improvement. From 
this data, it is clear that the drug was effective in reducing the difficulty in swallowing and these improvements 
has sustained effect during follow up. 
Table 13: Comparison of change in the difficulty in swallowing between study and control groups 
Difficulty in 
swallowing 




Study 20 0 
  
Control 20 2 
AFU 
Study 20 0 
  
Control 20 3 
The difference in the median values between the groups is greater than would expect by chance; there is a 
statistically significant difference. Thus, the study drug was too effective in reducing difficulty in swallowing 
than the control group.  
Table 14: Comparison of change in the foul breath within group and on subsequent follow-up 
Foul Breath Group No. Of patients Wilcoxon W value P value 
BT-AT 
Study 20 - 124 0.001 
Control 20 -12 0.135 
AT-AFU 
Study 20 -130 0.001 
Control 20 -11 0.125 
The comparison of the foul breath before treatment and after the treatment showed that there was remarkable 
improvement in the study group and it sustained after follow-up. This remarkable improvement is statistically 
significant (p=0.001). However, in the control group there was no significant improvement. From this data, it is 
clear that the drug was effective in reducing the foul breath and these improvements have sustained effect 
during follow up. 
Table 15: Comparison of change in the foul breath between study and control group 
Foul Breath Group No. Of patients Median Mann Whitney U test P value 
AT 
Study 20 1 
405 0.001 
Control 20 2 
AFU 
Study 20 1 
401 0.001 
Control 20 3 
Between group comparison the foul breath significantly reduced (p=0.001) both after treatment as well as 
follow-up period. Thus, the study drug was too effective in reducing foul breath in the study group than the 
control group. 
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Table 16: Comparison of change in the malaise on subsequent follow-up within group 
Malaise Group No. Of patients Wilcoxon W value P value 
BT-AT 
Study 20 - 73 0.001 
Control 20 -20 0.108 
AT-AFU 
Study 20 -73 0.001 
Control 20 -20 0.110 
The remarkable improvement is statistically significant (p=0.001).But in the control group there was no 
significant improvement. From this data it is clear that the drug was effective in reducing the malaise and there 
was sustained action even during follow up. 
Table 17: Comparison of change in the malaise between study and control group 
Malaise Group No. Of patients Median Mann Whitney U test P value 
AT 
Study 20 1 
405 0.058 
Control 20 1 
AFU 
Study 20 1 
413 0.043 
Control 20 2 
The malaise is significantly reduced (p=0.043) in the follow-up period but immediately after treatment the 
difference was not significant, difference was due to random sampling, (p=0.58).  
Table 18: Comparison of change in the mouth breathing on subsequent follow-up within group 
Mouth breathing Group No. of patients Wilcoxon W value P value 
BT-AT 
Study 20 - 30 0.001 
Control 20 -10 0.216 
AT-AFU 
Study 20 -43 0.001 
Control 20 -11 0.325 
This remarkable reduction is statistically significant (p=0.001). However, in the control group there was no 
significant improvement. This implies that the drug was effective in reducing the mouth breathing and there 
was sustained action even during follow up.  
Table 19: Comparison of mouth breathing between study and control group 
Mouth breathing Group No. Of patients Median Mann Whitney U test P value 
AT 
Study 20 2 
405 0.002 
Control 20 2 
AFU 
Study 20 1 
395 0.003 
Control 20 2 
The difference in the median values between the groups is greater than would expected by chance; there is a 
statistically significant difference implies that the trial drug was very effective in reducing the mouth breathing 
than that of the control group and further retained the effect during the follow-up period.  
Table 20: Comparison of change in the cough on subsequent follow-up within the group 
Cough Group No. Of patients Wilcoxon W value P value 
BT-AT 
Study 20 - 144 0.001 
Control 20 -120 0.001 
AT-AFU 
Study 20 -153 0.001 
Control 20 -131 0.001 
The remarkable improvement is statistically significant (p=0.001). In the control group there was also 
statistically significant reduction of cough (p=0.001).  
Table 21: Comparison of change in the cough between study and control group 
Cough Group No. Of patients Median Mann Whitney U test P value 
AT 
Study 20 1 
365 0.101 
Control 20 1 
AFU 
Study 20 1 
360 0.095 
Control 20 1 
The median value difference between two groups is due to the possibility of random sampling variability. The 
difference was not statistically significant. This implies that both the treatment were equally effective in 
reducing the cough.  
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Table 22: Comparison of change in the hoarseness of voice on subsequent follow-up within group 
Hoarseness of voice Group No. Of patients Wilcoxon W value P value 
BT-AT 
Study 20 - 68 0.001 
Control 20 -10 0.143 
AT-AFU 
Study 20 -130 0.001 
Control 20 -18 0.139 
The comparison of hoarseness of voice showed that there was remarkable improvement in the study group 
after the treatment as well as after follow-up. This remarkable improvement is statistically significant 
(p=0.001). However, in the control group there was no significant improvement. From this data, it is clear that 
the drug was effective in reducing the hoarseness of voice and there was sustained effect in the follow up 
period. 
Table 23: Comparison of change in hoarseness of voice between study and control group 
Hoarseness of voice Group No. of patients Median Mann Whitney U test P value 
AT 
Study 20 0 
410 0.029 
Control 20 1 
AFU 
Study 20 0 
398 0.040 
Control 20 1 
The difference in the median values between the groups is greater than would expected by chance; there is a 
statistically significant difference implies that the trial drug was very effective in reducing the hoarseness of 
voice than that of the control group and further retained the effect during the follow-up period.  
Table 24: Comparison of change in the choking spells at night on subsequent follow-up within group 
Choking spells at night Group No. of patients Wilcoxon W value P value 
BT-AT 
Study 20 - 52 0.005 
Control 20 -10 0.631 
AT-AFU 
Study 20 -52 0.005 
Control 20 -10 0.631 
The comparison of choking spells at night, which was a major symptom, showed that there was remarkable 
improvement in the study group after the treatment as well as after follow-up. This remarkable improvement is 
statistically significant (p=0.005). However, in the control group there was no significant improvement. From 
this data, it is clear that the drug was effective in reducing the choking spells at night and there was sustained 
action even during follow up. 
Table 25: Comparison of choking spells at night between study and control group 
Choking spells at night Group No. of patients Median Mann Whitney U test P value 
AT 
Study 20 0 
356 0.009 
Control 20 1 
AFU 
Study 20 0 
356 0.009 
Control 20 1 
The choking spells at night is statistically significant (p=0.009) both after treatment as well as follow-up period. 
This implies that the trial drug was very effective in reducing the choking spells at night than that of the control 
group and further retained the effect during the follow-up period.  
Table 26: Comparison of change towards reduction in the size of tonsils on subsequent follow-up within 
group 
Size of tonsils Group No. of patients Wilcoxon W value P value 
BT-AT 
Study 20 - 25 0.031 
Control 20 -5 0.935 
AT-AFU 
Study 20 -38 0.006 
Control 20 -5 0.956 
The comparison of size of tonsils showed that there was remarkable reduction of the sign in the study group 
after the treatment as well as after follow-up. This remarkable improvement is statistically significant 
(p=0.031). However, in the control group there was no significant improvement. From this data, it is clear that 
the drug was effective in reducing the size of tonsils in trial group and there was sustained action even during 
the follow 
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Table 27: Comparison of change towards reduction in the size of tonsils between study and control 
group 
Size of tonsils Group No. of patients Median Mann Whitney U test P value 
AT 
Study 20 0 
398 0.009 
Control 20 1 
AFU 
Study 20 0 
425 0.005 
Control 20 2 
The difference in the median values between the groups is greater than would expected by chance; there is a 
statistically significant difference, this implies that the trial drug was very effective in reducing the size of 
tonsils than that of the control group and further retained the effect during the follow-up period.  
Table 28: Comparison of yellowish beads of pus from crypts on subsequent follow-up within group 
Yellowish beads of pus from crypts Group No. of patients Wilcoxon W value P value 
BT-AT 
Study 20 - 135 0.003 
Control 20 -143 0.004 
AT-AFU 
Study 20 -131 0.002 
Control 20 -123 0.005 
The comparison of yellowish beads of pus from crypts showed that there was remarkable improvement in the 
study group after the treatment as well as after follow-up. This remarkable improvement is statistically 
significant (p=0.003). In the control group there was also significant improvement (P=0.004and p=0.005). 
From this data, it is clear that the drug and control drugs were effective in reducing yellowish beads of pus from 
crypts. 
Table 29: Comparison of yellowish beads of pus from crypts between study and control group 
Yellowish beads of pus from 
crypts 
Group No. of patients Median Mann Whitney U test P value 
AT 
Study 20 2 
410 0.001 
Control 20 2 
AFU 
Study 20 2 
405 0.002 
Control 20 2 
The difference in the median values between the groups is greater than would expect by chance; there is a 
statistically significant difference, even though the control drug is effective in reducing the symptom, trial drug 
was more effective in reducing the yellowish beads of pus from crypts of tonsils than that of the control drug 
and further retained the effect during the follow-up period.  
Table 30: Comparison of change in the congestion of pillars on subsequent follow-up within group 
Congestion of pillars Group No. of patients Wilcoxon W value P value 
BT-AT 
Study 20 - 139 0.001 
Control 20 -20 0.076 
AT-AFU 
Study 20 -160 0.001 
Control 20 -20 0.076 
The comparison of congestion of pillars showed that there was remarkable reduction of the sign in the study 
group after the treatment as well as after follow-up. This remarkable improvement is statistically significant 
(p=0.001). However, in the control group there was no significant improvement. From this data, it is clear that 
the drug was effective in congestion of pillars and there was sustained action even during follow up. 
Table 31: Comparison of change in the congestion of pillars between study and control group 
Congestion of pillars Group No. of patients Median Mann Whitney U test P value 
AT 
Study 20 0 
450 0.001 
Control 20 1 
AFU 
Study 20 0 
425 0.001 
Control 20 1 
The difference in the median values between the groups is greater than would expect by chance; there is a 
statistically significant difference. This implies that the trial drug was very effective in reducing the congestion 
of pillars than that of the control group and further retained the effect during the follow-up period.  
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Table 32: Comparison of change in the redness of soft palate on subsequent follow-up within group 
Redness of soft palate Group No. of patients Wilcoxon W value P value 
BT-AT 
Study 20 - 24 0.031 
Control 20 -12 0.235 
AT-AFU 
Study 20 -24 0.031 
Control 20 -12 0.235 
The comparison of redness of soft palate, which was a major clinical sign, showed that there was remarkable 
reduction of the sign in the study group after the treatment as well as after follow-up. This remarkable 
improvement is statistically significant (p=0.031). However, in the control group there was no significant 
improvement. From this data, it is clear that the drug was effective in reducing the redness of soft palate and 
there was sustained action even during follow up. 
Table 33: Comparison of change in the redness of soft palate between study and control group 
Redness of soft palate Group No. of patients Median Mann Whitney U test P value 
AT 
Study 20 2 
342 0.589 
Control 20 3 
AFU 
Study 20 2 
364 0.613 
Control 20 3 
The difference in the median value between the two groups is not great enough to exclude the possibility that 
the difference is due to random sampling variability. There is no statistical significant difference after treatment 
as well as after follow-up.  
Table 34: Comparison of change in the oedema of the uvula on subsequent follow-up within group 
Oedema of the uvula Group No. of patients Wilcoxon W value P value 
BT-AT 
Study 20 - 100 0.001 
Control 20 -12 0.122 
AT-AFU 
Study 20 -133 0.001 
Control 20 -12 0.135 
The comparison of oedema of the uvula, which was a major clinical sign, showed that there was remarkable 
improvement reduction of the sign in the study group after the treatment as well as after follow-up. This 
remarkable improvement is statistically significant (p=0.001). However, in the control group there was no 
significant improvement. From this data, it is clear that the drug was effective in reducing the oedema of the 
uvula and there was sustained action even during follow up. 
Table 35: Comparison of change in the oedema of the uvula between study and control group 
Oedema of the uvula Group No. of patients Median Mann Whitney U test P value 
AT 
Study 20 0 
425 0.001 
Control 20 1 
AFU 
Study 20 0 
433 0.001 
Control 20 1 
The difference in the median values between the groups is greater than would expect by chance; there is a 
statistically significant difference. This implies that the trial drug was very effective in reducing the oedema of 
the uvula attacks than that of the control group and further retained the effect during the follow-up period.  
Table 36: Comparison of change in the deviation of the uvula on subsequent follow-up within group 
Deviation of the uvula Group No. pf patients Wilcoxon W value P value 
BT-AT 
Study 20 - 98 0.001 
Control 20 -14 0.128 
AT-AFU 
Study 20 -100 0.001 
Control 20 -18 0.105 
The comparison of deviation of the uvula, which was a major symptom, showed that there was remarkable 
improvement in the study group after the treatment as well as after follow-up. This remarkable improvement is 
statistically significant (p=0.001). However, in the control group there was no significant improvement. From 
this data, it is clear that the drug was effective in reducing the attack of sore throat and there was sustained 
action even during follow up. 
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Table 37: Comparison of change in the deviation of the uvula between study and control group 
Deviation of the 
uvula 
Group No. of 
patients 
Median Mann Whitney U test P value 
AT 
Study 20 0 
410 0.001 
Control 20 1 
AFU 
Study 20 0 
415 0.001 
Control 20 1 
The difference in the median values between the groups is greater than would expect by chance; there is a 
statistically significant difference. This implies that the trial drug was very effective in reducing the deviation of 
the uvula attacks than that of the control group and further retained the effect during the follow-up period.  
Table 38: Comparison of lymph node enlargement on subsequent follow-up within group 
Lymph node enlargement Group No. of patients 




Study 20 - 55 0.005 
Control 20 -5 0.500 
AT-AFU 
Study 20 -55 0.002 
Control 20 -5 0.500 
The comparison of lymph node enlargement, which was a major clinical sign, showed that there was 
remarkable improvement in the study group after the treatment as well as after follow-up. This remarkable 
improvement is statistically significant (p=0.002). However, in the control group there was no significant 
improvement. From this data, it is clear that the drug was effective in reducing the lymph node enlargement 
and there was sustained action even during follow up. 
Table 39: Comparison of lymph node enlargement between study and control group 
lymph node 
enlargement 




Study 20 0 
410 0.004 
Control 20 1 
AFU 
Study 20 0 
410 0.004 
Control 20 1 
The difference in the median values between the groups is greater than would expect by chance; there is a 
statistically significant difference. This implies that the trial drug was very effective in reducing the lymph node 
enlargement than that of the control group and further retained the effect during the follow-up period.  
Table 40: Comparison of mean difference in the haemoglobin concentration between study group and 
control group 
Haemoglobin Concentration Mean Difference SD t-value P-value 
Study Group 1.47 0.65 
3.89 0.004 
Control Group 0.46 0.35 
From the above table it is clear that the comparison between before and after treatment between two groups, 
the haemoglobin concentration in study group has remarkably increasing than that of the control group. This 
mean difference is statistically significant (p=0.004). 
Table 41: Comparison of mean difference in the Lymphocytes count between study group and control 
group 
Lymphocyte Count Mean Difference SD t-value P-value 
Study Group 4.63 2.03  
3.49 
 
0.014 Control Group 1.85 1.68 
From the above table it is clear that the comparison between before and after treatment between two groups, 
the lymphocytes count in study group has remarkably decreasing than that of the control group. This mean 
difference is statistically significant (p=0.014). 
Table 42: Comparison of mean difference in the E.S.R between study group and control group 
E.S.R Mean Difference SD t-value P-value 
Study Group 8.54 3.21  
4.29 
 
0.001 Control Group 0.37 1.07 
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From the above table it is clear that the 
comparison between mean difference in before and 
after treatment between two groups, the E.S.R level 
in study group has remarkably decreasing than that 
of the control group. This mean difference is 
statistically significant (p=0.001). 
DISCUSSION 
Tonsillitis is an infection of the tonsils. 
Tonsillitis is an extremely common in children and 
young people but it can occur at any age. The 
pathogenesis of infectious or inflammatory disease in 
the tonsils most likely has its basis in their anatomic 
location and their inherent function as organ of 
immunity, processing infectious material, and other 
antigens and then becoming, ironically, a focus of 
infection or inflammation. No single theory of 
pathogenesis has yet been accepted, however viral 
infection with secondary bacterial invasion may be 
one mechanism of the initiation of chronic disease, 
but the effects of the environment, host factors, and 
the widespread use of antibiotics, ecological 
considerations, and diet all may play a role. Tonsillitis 
most often occurs in children; however, the condition 
rarely occurs in children younger than 2 years. Acute 
tonsillitis is a common condition often seen in 
children aged 5–10 and young adults aged 15–25. As 
such; a risk factor for tonsillitis is simply being at a 
young age. In addition, children attend school and 
while they are at school, they are in close contact 
with other children. They have frequent exposure to 
bacterial and viral infections, which can result in 
tonsillitis. 
Combination of Varabhrihatyadi Kashayam 
and Sarapunkha lepam is mentioned in the context of 
treatment of Apachi (a clinical condition similar to 
chronic lymphadenitis) in Arogyakalpadrumam, a 
traditional Ayurvedic pediatric text book. Though the 
drug is not directly indicated for Chronic Tonsillitis, it 
is taken as trial drug because tonsils are also in 
lymphoid origin. 
Due to indulging in prescribed aetiological 
factors Kapha and Pitha Dosha will get vitiated and 
thus vitiated Doshas circulates in Siras (Prasara) and 
get localised (Sthanasamshraya) around throat. This 
will results in the manifestation of Tundikeri. 
Agnimandya (suppression of digestive system) and 
Ama (morbid substances) formation being basic 
pathology of all diseases, these factors definitely 
present in the manifestation of Tundikeri. The 
Varabhrihthyadi Kashaya having following drugs 
Amalaki (Emblica officinale), Hareethaki (Terminalia 
chebula), Vibeethaki (Terminalia bellerica), Bhrihati 
(Solanum indicum), Nimba (Azadirachta indica), 
Rajani (Curcuma longa), Vrisha (Adathoda vasica), 
Devadaru (Cedrus deodar), Patola (Trichosanthes 
dioica) and Sarapunkha (Tephrosa purpurea). 
Hareetaki Vibhithaki and Amalaki are having 
Pachana (digestive), Deepana (carminative) and 
Anulomana (laxative) properties. Vibhithaki and 
Hareethaki are having Kapha and Pitha alleviating 
properties. Amalaki is having the potency to alleviate 
all Doshas with Kapha and Pitha predominance 
Bhrihathi, Sarapunkha and Devadaru are having 
Pachana (digestive) Muthrala (diuretic), Sodhahara 
(anti inflammatory) properties. Amalaki and 
Hareethaki are having Rasayana (rejuvinative) and 
Balya (immunomodulatory) actions. Nimba, Rajani 
Patola and Vrisha are having Pachana (digestive), 
Deepana (carminative) antimicrobial (Boothakhna) 
and immunomodulory actions (Balya). Topical 
application of Sarapunkha provides anti 
inflammatory effect. 
At a glimpse the total potential of the study 
formulation can be attributed to following headings: 
 Hareetaki Vibhithaki and Amalaki, Rajani, Nimba, 
Patola and Vrisha are having Pachana (digestive) 
and Deepana (carminative) properties. Thus they 
have the potency to promote digestive system and 
have the capacity to eliminate the morbid 
substance (Ama).  
 Hareetaki Vibhithaki and Amalaki, Rajani, Nimba, 
Sarapunkha and Patola are having a cumulative 
effect on alleviating the vitiated Kapha and Pitha 
Doshas. Thus controlling infection and 
inflammatory process in chronic tonsillitis. 
 Rajani, Nimba and Vrisha Amalaki, Hareethaki and 
Vibeethaki are having immunomodulatory action. 
Thus preventing recurrence of infection. 
 Sarapunkha is having anti-inflammatory property 
when it is used as a topical application. In this trial 
Varabhrihatyadi kashaya is providing internal 
purification and immunomodulatory action and 
Sarapunkha lepa is providing supportive local anti 
inflammatory action. 
Overall, this combination has controlled infection, 
reduced inflammation, and recurrence of chronic 
tonsillitis. 
The comparison of frequency of the recurrent 
attacks of sore throat, which was a major symptom, 
showed that there was remarkable improvement in 
the study group after the treatment as well as after 
the follow-up. This remarkable improvement is 
statistically significant (p=0.001). However, in the 
control group there was no significant improvement.. 
This implies that the trial drug was very effective in 
reducing the recurrence of sore throat than that of 
the control group and further retained the effect 
during the follow-up period.  
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The comparison of the irritation in the throat 
within the study and control group of patients 
revealed highly significant improvement (p=0.001) 
after treatment and subsequent follow-up. However, 
the difference in the median value between the two 
groups is not great enough to exclude the possibility 
that the difference is due to random sampling 
variability. There is no statistical significant 
difference after treatment as well as after follow-up. 
This shows that both the treatments were equally 
effective in reducing irritation of throat.  
The comparison of the pain in throat in the 
study group showed that there was significant effect 
(p=0.001) after the treatment as well as after follow-
up. In the control group, this effect was not 
statistically significant. Thus, it proved that trial drug 
was very effective in reducing the pain. There was 
statistically significant difference in the median 
values between the groups. 
There was significant reduction in the 
difficulty in swallowing in the study group (p < 
0.001) whereas in control group there was no 
change. Comparison of two groups showed that the 
difference in the median values between the groups 
is greater than would expected by chance; there is a 
statistically significant difference. Thus, the study 
drug was too effective in reducing difficulty in 
swallowing than the control group.  
Comparison of the symptom malaise showed 
that there was remarkable improvement in the study 
group after the treatment as well as after the follow-
up. This remarkable improvement is statistically 
significant (p=0.001). But in the control group there 
was no significant improvement. Between the group 
analysis highlighted that the malaise is significantly 
reduced (p=0.043) in the follow-up period but 
immediate after treatment the difference was not 
significant, so difference was due to random sampling 
(p=0.58).  
  Comparison of the symptom mouth breathing 
showed that there was a reduction in the symptom in 
the study group after the treatment as well as after 
follow-up. This remarkable reduction is statistically 
significant (p=0.001). However, in the control group 
there was no significant improvement. Between the 
two-group analysis, the difference in the median 
values between the groups is greater than would 
expected by chance; there is a statistically significant 
difference implies that the trial drug was very 
effective in reducing the mouth breathing than that of 
the control drug and further retained the effect 
during the follow-up period.  
The comparison of change in the cough 
showed that there was remarkable reduction of the 
symptom in the study group after the treatment as 
well as after follow-up. This remarkable 
improvement is statistically significant (p=0.001). In 
the control group there was also statistically 
significant reduction of cough (p=0.001). However, 
the difference in the median value between the two 
groups is not great enough to exclude the possibility 
that the difference is due to random sampling 
variability. There is no statistical significant 
difference after treatment as well as after follow-up 
(p=0101, p=0.095). This shows that both the 
treatments were equally effective in reducing 
irritation of throat. This effect in the control group 
may be due to combined effect of interventional drug 
and general instruction followed by control group. 
The comparison of hoarseness of voice 
showed that there was remarkable improvement in 
the study group after the treatment as well as after 
follow-up. This remarkable improvement is 
statistically significant (p=0.001). However, in the 
control group there was no significant improvement. 
Between the two group analysis, the difference in the 
median values between the groups is greater than 
would expected by chance; there is a statistically 
significant difference, implies that the trial drug was 
very effective in reducing the hoarseness of voice 
than that of the control drug and further retained the 
effect during the follow-up period. 
The comparison of choking spells at night, 
which was a major symptom, showed that there was 
remarkable improvement in the study group after the 
treatment as well as after follow-up. This remarkable 
improvement is statistically significant (p=0.005). 
However, in the control group there was no 
significant improvement. Between the two group 
analysis, the choking spells at night is statistically 
significant (p=0.009) both after treatment as well as 
follow-up period. This implies that the trial drug was 
very effective in reducing the choking spells at night 
than that of the control group and further retained 
the effect during the follow-up period. 
The comparison of size of tonsils showed that 
there was remarkable improvement in the study 
group after the treatment as well as after follow-up. 
This remarkable improvement is statistically 
significant (p=0.031). But in the control group there 
was no significant improvement. Between the group 
analysis clarified that the difference in the median 
values between the groups is greater than would 
expected by chance; there is a statistically significant 
difference, this implies that the trial drug was very 
effective in reducing the size of tonsils than that of 
the control group and further retained the effect 
during the follow-up period. 
The comparison of yellowish beads of pus 
from crypts showed that there was remarkable 
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improvement in the study group after the treatment 
as well as after follow-up. This remarkable 
improvement is statistically significant (p=0.003). In 
the control group there was also significant 
improvement (P=.004). The difference in the median 
values between the groups is greater than would 
expected by chance; there is a statistically significant 
difference, this implies that even though the control 
trial is effective in reducing the symptom trial drug 
was more effective in reducing the yellowish beads 
from the crypts than that of the control group and 
further retained the effect during the follow-up 
period. 
The comparison of congestion of pillars 
showed that there was remarkable improvement in 
the study group after the treatment as well as after 
follow-up. This remarkable improvement is 
statistically significant (p=0.001). However, in the 
control group there was no significant improvement. 
Between the two groups analysis showed that, there 
is statistically significant difference between two 
groups in reducing the symptoms, which implies 
superiority of the trial drug over the control. 
The comparison of redness of soft palate, 
which was a major clinical sign, showed that there 
was remarkable improvement in the study group 
after the treatment as well as after follow-up. This 
remarkable improvement is statistically significant 
(p=0.031). However, in the control group there was 
no significant improvement. Between the two-group 
analyses, the redness of soft palate was not 
statistically significant between trial drug group and 
control group. There is no statistical significant 
difference after treatment as well as after follow-up. 
(p=0.589and p=0.613). This shows that both the 
treatments were equally effective in reducing 
redness of soft palate.  
The comparison of oedema of the uvula, 
which was a major clinical sign, showed that there 
was remarkable improvement in the study group 
after the treatment as well as after follow-up. This 
remarkable improvement is statistically significant 
(p=0.001). Nevertheless, in the control group there 
was no significant improvement. Between the two-
group analyses, the difference in the median values 
between the groups is greater than would expect by 
chance; there is a statistically significant difference. 
This implies that the trial drug was very effective in 
reducing the oedema of the uvula attacks than that of 
the control group and further retained the effect 
during the follow-up period.  
The comparison of deviation of the uvula, 
which was a major sign, showed that there was 
remarkable improvement in the study group after the 
treatment as well as after follow-up. This remarkable 
improvement is statistically significant (p=0.001). 
However, in the control group there was no 
significant improvement. Between the two-group 
analyses, the difference in the median values 
between the groups is greater than would expect by 
chance; there is a statistically significant difference. 
This implies that the trial drug was very effective in 
reducing the deviation of the uvula attacks than that 
of the control group and further retained the effect 
during the follow-up period. 
The comparison of lymph node enlargement, 
which was a major clinical sign, showed that there 
was remarkable improvement in the study group 
after the treatment as well as after follow-up. This 
remarkable improvement is statistically significant 
(p=0.002). However, in the control group there was 
no significant improvement. Between the two group 
analysis the difference in the median values between 
the groups is greater than would expected by chance; 
there is a statistically significant difference. This 
implies that the trial drug was very effective in 
reducing the lymph node enlargement than that of 
the control group and further retained the effect 
during the follow-up period. 
In total, the trial drug was effective in 
reducing recurrent attacks of sore throat, irritation in 
the throat, pain in the throat, pain on swallowing, 
difficulty in swallowing, malaise, mouth breathing, 
halitosis, cough, hoarseness of voice, choking spells at 
night, size of the tonsil, congestion of pillars, oedema 
of the uvula, deviation of the uvula, redness of soft 
palate, lymph node enlargement, yellowish pus from 
crypts. 
 However, in the control group there was no 
significant change over the symptoms like recurrent 
attacks of sore throat, pain in the throat, pain on 
swallowing, difficulty in swallowing, malaise, mouth 
breathing, halitosis, hoarseness of voice, choking 
spells at night, size of the tonsil, congestion of pillars, 
oedema of the uvula, deviation of the uvula, and 
lymph node enlargement. 
Both study drug and control drug were 
equally effective in reducing the following symptoms 
i.e. irritation of the throat, cough and redness in the 
soft palate. This may be due to the combined effect of 
interventional drug strict diet restriction and 
regiments followed by control group. It all can also be 
attributed to sampling variations. 
The control drug was effective in reducing the 
yellowish beads of pus from crypts but between the 
group evaluations showed that study drug was much 
more effective than the control drug. This effect in 
control group may be due to strict diet restriction 
and regiments followed by the control group.  
Int. J. Ayur. Pharma Research, 2019;7(7):1-16 
     Available online at: http://ijapr.in  16 
The comparison between before and after 
treatment of haemoglobin between two groups 
showed that, the haemoglobin concentration in study 
group has remarkably increased than that of the 
control group. This mean difference is statistically 
significant (p=0.004). This effect is maintained during 
the follow up period also. Control of the infection 
may have raised the haemoglobin concentration, due 
to enhanced general health status. 
Evaluation of the change in the Lymphocyte 
count before and after treatment between two 
groups reveals that, the lymphocytes count in study 
group has remarkably decreasing than that of the 
control group. This mean difference is statistically 
significant (p=0.014). Lymphocyte count is usually 
elevated in gram-positive pus forming bacterial 
infections. Statistically significant reduction of 
lymphocyte count implied the control of the infection. 
The comparison between before and after treatment 
between two groups, the lymphocytes count in study 
group has remarkably decreasing than that of the 
control group. This mean difference is statistically 
significant (p=0.014). 
The comparison between mean difference of 
E.S.R before and after treatment between two groups 
showed that the E.S.R level in study group has 
remarkably decreased than that of the control group. 
This mean difference is statistically significant 
(p=0.001). E.S.R value will be elevated during an 
infection and reduction of E.S.R indicates control of 
infection 
 CONCLUSION 
1) Combination of Varabhrihatyadi Kashaya and 
Sarapunkha Lepa is effective in reducing the 
majority of signs and symptoms of Chronic 
Tonsillitis. 
2) Combination of Varabhrihatyadi Kashaya and 
Sarapunkha Lepa is effective `in reducing the 
number of attacks of Chronic Tonsillitis. 
3) Topical application of Sarapunkha has provided 
additional anti-inflammatory effect. 
4) Combination of Varabhrihatyadi Kashaya and 
Sarapunkha Lepa has provided sustained effect. 
5) The alternate hypothesis, combination of 
Varabhrihatyadi Kashaya and Sarapunkha Lepa is 
effective in reducing the signs and symptoms of 
Chronic Tonsillitis in children” was accepted. 
AKNOWLWDGEMENTS 
I sincerely express my indebtedness and 
profound gratitude to my esteemed guides Dr. S.K. 
Ramachandran M.D (Ay), Professor, Department of 
Kaumarabhritya, Government Ayurveda College, 
Thiruvananthapuram and Dr. Mini. S. Muraleedhar, 
M.D (Ay), M.D (Ay), Associate Professor, Department 
of Kaumarabhritya, Government Ayurveda College, 
Kannur, for their constant inspiration, excellent 
guidance, valuable suggestions and creative 
affirmation at every stage of this work. 
 REFERENCES 
1. Susrutha, Susrutha samhitha, Reprinted on 2010, 
Varanasi: Chaukhambha Sanskrit Sansthan, 
Nidanasthana - 11/10-12, Page No.312. 
2. Vagbhata, Astanga Hridayam, Reprinted on 2010, 
Varanasi: Chaukhambha Sanskrit Sansthan, 
Uttarastana - 21/45. Page No.849. 
3. Susrutha Susrutha samhitha, Reprinted on 2010, 
Varanasi: Chaukhambha Sanskrit Sansthan, 
Nidanasthana - 16/40. Page No.333. 
4. Vagbhata, Astanga Hridayam, Reprinted on 2010, 
Varanasi: Chaukhambha Sanskrit Sansthan, 
Uttarastana - 21/47. Page No.849 . 
5. Kaikulangara rama vaidyan, Arogya 
kapadrumam, sixth edition, sulabha books, 2002 
december, page no:400. 
6. Kaikulangara rama vaidyan, Arogya 
kapadrumam, sixth edition, sulabha books, 2002 









Disclaimer: IJAPR is solely owned by Mahadev Publications - dedicated to publish quality research, while every effort has been taken to 
verify the accuracy of the content published in our Journal. IJAPR cannot accept any responsibility or liability for the articles content 
which are published. The views expressed in articles by our contributing authors are not necessarily those of IJAPR editor or editorial 
board members.  
 
Cite this article as:  
Sujith S, Binitha P. The Combined Effect of Varabhrihatyadi Kashaya and 
Sarapunkha Lepa in Chronic Tonsillitis in Children. International Journal 
of Ayurveda and Pharma Research. 2019;7(7):1-16. 
Source of support: Nil, Conflict of interest: None Declared 
 
*Address for correspondence 
Dr. Sujith S,  
Medical Officer, Kailathu House, 
Omalloor PO, Pathanamthitta, Pin:-
687643 
Email: drsujiths@gmail.com  
Phone No: 9633648020 
